Bristol Myers Squibb Receives European Commission Approval of Reblozyl (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia
Third authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with diseases impacted by anemia Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission